Cardiol Therapeutics (TSE:CRDL) Stock Price Down 14.6% – Should You Sell?

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) traded down 14.6% during trading on Tuesday . The company traded as low as C$1.24 and last traded at C$1.29. 551,069 shares changed hands during trading, an increase of 405% from the average session volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The company has a market capitalization of C$133.00 million, a price-to-earnings ratio of -3.24 and a beta of 1.31. The firm’s 50-day simple moving average is C$1.49 and its two-hundred day simple moving average is C$1.64.

Cardiol Therapeutics (TSE:CRDL) last announced its quarterly earnings results on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. Sell-side analysts predict that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.